Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics is supported by a strengthened clinical profile for ivonescimab, as HARMONi-2 improved to an OS HR of 0.73 at 234 deaths from 0.777 at 157 deaths, with median OS of 30.75 versus 22.57 months, easing concerns around survival durability. The data also suggest meaningful efficacy versus pembrolizumab control, with a 50.0% ORR and 0.51 PFS HR, while the 8.18-month median OS gain indicates competitive potential in a market still benchmarked by sac-TMT plus pembrolizumab’s 0.35 PFS HR and 70.2% ORR. Although sac-TMT remains the standard to beat and HARMONi-3 in 2H26 is the key global test, the current readout supports a constructive view on Summit’s ability to build a leading next I/O backbone.

Summit Therapeutics is facing a fundamentally weak investment case because the company’s early efficacy signals have become less convincing as follow-up matures, with H-6’s PFS hazard ratio worsening from 0.60 to 0.72 while H-2 still shows an immature OS HR of about 0.78 across only 157 events and 39% of patients. The absence of updated mature OS evidence, plus H-3’s failure to accelerate timing despite a shared squamous design and overlap in China sites, raises doubt that the China data will translate cleanly into global clinical or commercial value. Safety and tolerability also remain a concern, since the cited combinations have shown elevated Grade ≥3 toxicities, and that burden could limit dose intensity and narrow the addressable opportunity even if efficacy holds.